Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).
M. D. Michaelson
Consultant or Advisory Role - Abbott Laboratories; AVEO; Genentech; Novartis; Pfizer; Wyeth
Research Funding - Abbott Laboratories; Bayer; Genentech; GlaxoSmithKline; Novartis; Pfizer; Wyeth
S. Oudard
No relevant relationships to disclose
Y. Ou
No relevant relationships to disclose
L. Sengeløv
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Sanofi
Research Funding - Celgene; Pfizer; Sanofi
Other Remuneration - Pfizer
F. Saad
Research Funding - Pfizer
N. Houede
Other Remuneration - Pfizer
P. J. Ostler
Other Remuneration - Pfizer
A. Stenzl
No relevant relationships to disclose
G. Daugaard
Honoraria - LEO Pharma; Pfizer; Roche
R. J. Jones
Research Funding - Pfizer
F. Laestadius
Employment or Leadership Position - Roche
A. Bahl
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
D. E. Castellano
No relevant relationships to disclose
J. Gschwend
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
T. Maurina
No relevant relationships to disclose
D. Ye
No relevant relationships to disclose
I. Chen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
S. Wang
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
E. C. Maneval
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer